Patent · US Active

Use of IL-31RA monoclonal antibodies for treating neuronal inflammation

US9828431B2 · kind B2 · utility

0Cited by
37References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 16, 2017
Grant dateNov 28, 2017
Priority date—
Expiry dateMar 16, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.